… Medical School. Can you discuss emerging second- and third-line treatment … of a large multicenter trial looking at Sutent (sunitinib) versus IDRX … second and third line of treatment. So those are the … there are some phase 1 trials looking at the combination of …

… there are now several trials have supported the use … Medicine, moderated a discussion on how to select treatment … several TKIs, including sunitinib [Sutent], cabozantinib, and lenvatinib [Lenvima … Lobins, DO: The SUNNIFORECAST trial [NCT03075423] mirrors the …

… of Internal Medicine at Mayo Clinic, discusses the CABINET trial (NCT03375320) … months set by sunitinib (Sutent), another TKI approved in … [treatment], if you will, and was approved by the FDA for … the [Alliance for Clinical Trials in Oncology]. Dr Jennifer …

… in the Department of Medical Oncology & … guidelines for second-line treatments, while emphasizing the … , pazopanib [Votrient], sunitinib [Sutent], bevacizumab [Avastin], etc, … pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer …

… features, biologies, and treatment responses. nccRCC histologies include … excluded from RCC clinical trials, which mainly enrolled … led investigator-initiated randomized trial, patients with untreated … TKI) monotherapy with sunitinib (Sutent). The study met its …

… Sarcoma Unit and a medical oncologist at The Royal … , randomized phase 3 IMADGIST trial. IMADGIST evaluated maintenance imatinib … 2 randomized trials which will hopefully guide treatment in the … receive ripretinib or sunitinib [Sutent]. The primary end point …

… a consultant medical oncologist, professor of medical oncology, and … in the evolving treatment landscape for patients with … recently completed trials. The phase 3 INSIGHT trial (NCT05734105) … (Qinlock) or sunitinib (Sutent), with progression-free survival …

… ) over placebo. Following treatment with ozekibart, patients’ median … face competition from Servier Pharmaceuticals’ IDH inhibitor, Tibsovo … ) master trial. This study found that Opdivo plus Sutent (sunitinib … , the biotech is now exploring the drug in other …

… associate professor of medicine at Harvard Medical School, both … pNETs, sunitinib [Sutent] is an FDA approved option. However … pause treatment or reduce the dose. In the trial, … ;www.fda.gov/drugs/;resources-information-approved-drugs/fda-approves- …

… biomarker could help inform treatment selection in the frontline … and director of Genitourinary Medical Oncology Research in New … ] phase 3 KEYNOTE-426 trial [NCT02853331], pembrolizumab [Keytruda] … was compared against sunitinib [Sutent] monotherapy, which was …